RxDoctor Payments Data

Noreen Kelly, MD

Cardiovascular Disease · Charlotte, NCNPI 1366737058

Payments from drug & device makers

$83,965in general payments, 2019–2025

Across 165 payments — averaging $508.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$52K
  • Abbott$26K
  • Edwards Lifesciences$5K
  • Siemens Medical Solutions USA, Inc.$200
  • Medtronic$183
  • E.r. Squibb & Sons, L.L.C.$159
  • plus $248 from 7 others
$6,900in research payments, 2019–2025

Across 1 payment — averaging $6900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Caption Health, Inc.$7K

What the payments were for

  • Consulting fees$12,14514%
  • Speaking & faculty fees$59,53171%
  • Travel & lodging$8,10110%
  • Food & beverage$4,1885%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$83,965 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$87,572
Medicare patients
357
Services billed
6,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$92,529
XareltoRivaroxaban24$32,403
EntrestoSacubitril/Valsartan16$27,886
Torsemide21$570
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$505
Valsartan12$504
Atorvastatin Calcium67$460
Metoprolol Succinate40$349
Losartan Potassium47$343
Carvedilol42$338
Rosuvastatin Calcium32$295
Amlodipine Besylate55$239
Furosemide31$237
Potassium Chloride13$211
Lisinopril23$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$38$27,88616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →